Category Archives: Biotechnology

20th World Congress on Biotechnology and Biotech Industries Meet during March 05-07, 2018 at London, UK with a theme Future prospects for Biotechnology and Economic Growth. Conference Series LLC through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. Scope and Importance Biotech Congress 2018 Conference aims to bring together the Professors, Researchers, scientists, business giants, and technocrats to provide an international forum for the dissemination of original research results, new ideas and practical development and discover advances in the field of biotechnology, management and education in relation to biotechnology as well as a breadth of other topics. The applications of biotechnology include therapeutics, diagnostics, genetically modified crops for agriculture, processed food, bioremediation, waste treatment, and energy production. Biotech Congress 2018 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists. Like what you just read? You can find similar content on the communities below. To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free Link: 20th World Congress on Biotechnology and Biotech Industries Meet - Technology Networks … Continue reading →

Puma Biotechnology, Inc. (NASDAQ:PBYI)market capitalization at present is $3.29B at the rate of $89.95 a share. The firms price-to-sales ratio was noted 0.00 in contrast with an overall industry average of 100.62. Most of the active traders and investors are keen to find ways to compare the value of stocks. The price-to-sales ratio offers a simple approach in this case. They just need to take the companys market capitalization and divide it by the companys total sales over the past 12 months. The lesser the ratio, the more attractive the investment. During the key period of last 5 years, Puma Biotechnology, Inc. (NASDAQ:PBYI) earnings per share growth remained at -44.40%. How Company Returns Shareholders Value? Dividends is a reward scheme, that a company presents to its shareholders. There can be various forms of dividends, such as cash payment, stocks or any other form. This payment is usually a part of the profit of the company. A companys dividend is mostly determined by its board of directors and it requires the shareholders approval.Puma Biotechnology, Inc. (NASDAQ:PBYI)for the trailing twelve months paying dividend with the payout ratio of 0.00% to its shareholders. Currently it is offering a dividend yield of 0.00% and … Continue reading →

Joe Cox, Ph.D., Bolder BioTechnology's President said: "Initiation of this clinical trial represents a major milestone for Bolder BioTechnology and the culmination of many years of effort by our dedicated and talented employees." "BBT-015 is a novel G-CSF analog that exhibits a longer duration of action and greater potency than other G-CSF products. In preclinical studies, BBT-015 stimulated larger and longer-lasting increases in neutrophils, and faster neutrophil recovery in chemotherapy-treated, neutropenic animals compared to other G-CSF products.BBT-015 also significantly increased survival and accelerated recovery of neutrophils, platelets, and red blood cells in animals exposed to lethal doses of radiation, even when administered 24 hours following radiation exposure." "BBT-015's increased potency and longer duration of action may stimulate faster neutrophil recovery in cancer patients and / or allow the drug to be administered less frequently and at lower doses than competing G-CSF products, with associated cost savings for patients." "G-CSF products are some of the best selling biopharmaceuticals in the world, with annual worldwide sales exceeding $6 billion, primarily from the treatment of neutropenia in cancer patients." About BBT-015BBT-015 is a long-acting G-CSF analog produced using site-specific PEGylation technology.G-CSF is a human protein that stimulates production of neutrophils, a type of … Continue reading →

The August issue of the New Jersey State Bar Association's bi-monthly magazine, New Jersey Lawyer, focuses on the evolving topic of biotechnology, genetics and the law. "Although a very specialized area, biotechnology law crosses many legal disciplines, including litigation, licensing, intellectual property, patents, agriculture, business, venture capitalism, antitrust, biosecurity and bioethics," said Angela Foster and David Opderbeck, who served as special editors for the issue. "The use of biotechnology has raised a number of legal, ethical and social issues, including who owns genetically modified organisms (GMOs), whether genetically modified foods are safe to eat, and who controls a person's genetic information. This issue explores contemporary biotechnology issues impacting the legal community." A dozen articles explore the topic in the award-winning magazine, beginning with a look at whether organs-on-chips are patentable in an article by Douglas Bucklin. Richard Catalina Jr.'s article on the Biologics Price Competition and Innovation Act follows. Nancy Del Pizzo's article looks at the open source model in biotechnology, while Foster explores the truth and fiction behind genetically modified food. Jonathan Lourie reviews strategic licenses and collaborations. Reproduction is the topic of two articles, one analyzing assisted reproductive technology, written by Alan Milstein, and one penned by Kimberly … Continue reading →

Biotechnology is also widespread in the medical sector Shumbeyi MuzondoCorrespondentBiotechnology is biologys fastest growing discipline prompted by the ever-increasing demand for food and fuel in a cleaner and greener environment. In general, biotechnology encompasses a wide array of technologies that use living systems to produce useful products and services. Integrating biotechnology into the agricultural system is critical to better use limited resources, increase agricultural yields and decrease the detrimental effects of using pesticides and chemical fertilisers. Agricultural biotechnology is a field of agricultural science which uses cell and molecular biology tools to improve genetic makeup and agronomic management of crops and animals. There are many biotechnology techniques employed by scientists and researchers in this discipline which include genetic engineering,marker assisted selection,hybridisation, plant tissue culture, biofertiliser technology, artificial insemination technology,plant and livestock disease diagnostics as well as vaccine production. The use of these biotechnology tools in Zimbabwe has the potential to improve the livelihoods of about 7,6 million people living in the rural areas and depending mainly on agriculture. Biotechnology being applied to a tomato plant Recombinant DNA technology This is a technology in which a plant or animal can receive genetic material (DNA) from a different organism to improve its … Continue reading →

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra: Privacy Policy (Updated: October 8, 2015): hide JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy. JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies. The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into … Continue reading →

Venture capitalist Seventure Partners announced that it has participated in a US$13m financing of Japanese biotech company Anaeropharma Science. The investment is made from Seventures Health for Life Capital investment vehicle. Anaeropharma Science is based in Tokyo. It develops novel genetically enhanced bacteria to fight tumours. The companys lead product APS001F is based on an obligate anaerobic bacterium. Bifidobacterium longum can only proliferate in the hypoxic core of solid tumours, where it secretes the enzyme cytosine deaminase turning a systemically administered prodrug into a cytotoxic agent, which hollows out the tumour from the inside. The company is currently conducting a Phase Ib/IIa trial of APS001F in patients with advanced solid tumours in the USA. Lead investor Seventure points out that the investment of US$13.2m (11.6m) will strengthen a Japanese leader in the microbiome sector. Anaeropharma will use the financing to accelerate the development of multiple programmes based on its proprietary platform technology. Seventure Partners invests alongside Novartis Pharma and Japanese investors Shinsei Corporate Investment Limited, Innovation Network Corporation of Japan and Mitsubishi UFJ Capital. This is Seventures first investment in a Japanese company, the Paris-based venture capital firm declared. There is a huge market opportunity for novel treatments that harness … Continue reading →

Sessions & Tracks Track 1: Advancements in Biotechnology Biotechnology is an ever emerging field in which biological processes, organisms, cells and cellular components are exploited to develop novel expertise. Over the past two decades there have been revolutionary biotech innovations which helped the mankind. New tools and products developed by biotechnologists are expedient in research, agriculture, industry and the clinic. Recent advancements in the field of biotechnology will underpin our economy and provide solutions to intractable problems of human and animal diseases, climate change, fuel alternatives, food security as well as improving our quality of life. Related:Biotechnology Conferences|Biotechnology Meetings|Biotechnology Conventions| biotechnology| biotech marketing| what does a biotechnologist do|biotechnology major | current events biotechnology 15th World Congress on Biotechnology and Biotech Industries Meet, March 20-22, 2017 at Rome, Italy; Biotechnology 2017, August 21-23, 2017 at Chicago, USA; 17thEuro Biotechnology Congress, September 25-27, 2017 at Berlin, Germany; Global Biotechnology Congress, Oct 9-11, 2017 at Auckland, New Zealand; 15thInternational Pharmaceutical Microbiology and Biotechnology Conference, June 21-23, 2017 at London, UK; 2ndInternational Conference on Bioscience and Biotechnology, March 9-10, 2017 at Colombo, Sri Lanka; BIO World Congress on Industrial Biotechnology, July 23-26, 2017 at Montreal, Canada; BioTech 2017, June 13-17 at Prague, Czech Republic; … Continue reading →

Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer. The study conducted at the National Center for Tumor Diseases in Heidelberg (Germany) will investigate the impact of NOX-A12 (olaptesed pegol) as a monotherapy on immune cell infiltration into tumors. In addition, Noxxon and Merck & Co will assess safety and efficacy of NOX-A12 in combination with Keytruda (pembrolizumab), Merck & Co./MSDs programmed death receptor-1 (PD-1) immune checkpoint-blocking antibody drug. The open-label trial (NCT03168139) is composed of two parts: patients will receive NOX-A12 monotherapy for two weeks, followed by combination therapy of NOX-A12 plus pembrolizumab for up to two years. 20 patients will be enroled: 10 patients for each metastatic pancreas and colorectal cancer. The design of the clinical trial was a collaborative effort between NOXXON and MSD. Part 1 of the study, in which patients will receive NOX-A12 monotherapy for up to two weeks, will evaluate immune infiltrate changes within the tumor microenvironment induced by CXCL12 inhibition with NOX-A12 by comparing pre- and post-treatment biopsy specimens as well … Continue reading →

Puma Biotechnology, (NYSE:PBYI) is a $3.2 billion market cap company initially focused on developing tyrosine kinase inhibitor neratinib (PB272) for HER2 positive breast cancer. The company has conducted 11 clinical trials for its lead candidate, with over 2,000 patients contributing to a favorable risk-benefit profile, per inflection point clinical trial readouts over the past quarter. Oncologic Drugs Advisory Committee (ODAC) at FDA recently voted for approval of neratinib in HER2 positive extended adjuvant treatment of early stage breast cancer in May 2017. ODAC vote is not binding but carries strong weight in the decision-making process. Given FDA director Gottlieb's new aggressive policies regarding the slow and outdated drug approval process at FDA, this was seen by the market as a "sure thing". The company is advancing neratinib in discussions with EMA for European markets, with validation in August 2016. Other investigations include neratinib in combinatory therapy for metastatic breast cancer and in solid tumors as well. Neratinib blocks signal cascades of epidermal growth factor receptors or EGFRs, specifically: HER1, HER2, HER3, and HER4. A number of studies are showing nice anti-tumor efficacy. Taken together with ODAC favor, Phase 3 result emphasis for neratinib which met primary endpoints appears to have … Continue reading →